Jounce Therapeutics, Inc.
JNCE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for JNCE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
gs-1811 (Phase 1)
Next Catalyst
—
Financial data as of Dec 31, 2022.
Tracking 6 pipeline candidates for Jounce Therapeutics, Inc..
Run Jounce Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Jounce Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 2
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is Jounce Therapeutics, Inc.'s lead drug candidate?
Jounce Therapeutics, Inc.'s most advanced tracked candidate is gs-1811 (Phase 1) for Solid tumors.
Who is the CEO of Jounce Therapeutics, Inc.?
Richard Murray, Ph.D. is the chief executive officer of Jounce Therapeutics, Inc. (JNCE).
What therapeutic areas does Jounce Therapeutics, Inc. focus on?
Jounce Therapeutics, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.